Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 26-May 2015. Module: Canada Health Infoway English module (core metadata concept)
Descriptions:
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Varicella-zoster vaccine (product) | false | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Varicella virus vaccine (substance) | false | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | Plays role | Active immunity stimulant role (role) | true | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Varicella-zoster live attenuated vaccine | false | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Vaccine product containing only Human alphaherpesvirus 3 antigen for herpes zoster prevention (medicinal product) | true | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | Count of base of active ingredient | un | false | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Product manufactured as parenteral dose form (product) | true | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | Has supplier | Merck Canada Inc. (supplier) | true | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | a une forme pharmaceutique (attribut) | forme pharmaceutique pour usage parentéral (forme pharmaceutique) | true | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Live attenuated Human alphaherpesvirus 3 Oka-Merck strain antigen | true | Inferred relationship | Some | 1 | |
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Live attenuated Human alphaherpesvirus 3 Oka-Merck strain only vaccine product | true | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | est un(e) (attribut) | Varicella-zoster live attenuated vaccine (product) | false | Inferred relationship | Some | ||
| ZOSTAVAX II 19400 plaque forming units per 0.65 milliliter powder and diluent for suspension for injection Merck Canada Inc. (real clinical drug) | a pour principe actif (attribut) | Varicella virus live vaccine (substance) | false | Inferred relationship | Some | 1 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
Administered tradename codes for vaccines reference set (foundation metadata concept)
FHIR